2021
DOI: 10.21203/rs.3.rs-374465/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Identifying Potential Novel Pathways and Therapeutic Targets of Major Depressive Disorder with Functional Genomics

Abstract: Background: Major depressive disorder (MDD) is a debilitating illness and a leading cause of disability, but its pathophysiology remains to be completely elucidated. Resistance to traditional antidepressant treatment is highly prevalent within patient populations. Ketamine, a rapid-acting antidepressant that has shown success in treating resistant patients, is hypothesized to function by modulating excitatory and inhibitory neurotransmitters. This has led to a paradigm shift from the monoaminergic hypothesis, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 117 publications
0
0
0
Order By: Relevance